Increase in IL-6 levels among major depressive disorder patients after a 6-week treatment with duloxetine 60 mg/day: a preliminary observation

BACKGROUND: Immune modifications, including changes in interleukin (IL)-6 levels, have often been observed in major depressive disorder (MDD) during treatment with selective serotonin reuptake inhibitors (SSRIs) or the serotonin norepinephrine reuptake inhibitor (SNRI) venlafaxine. Nevertheless, no...

Descripción completa

Detalles Bibliográficos
Autores principales: Fornaro, Michele, Martino, Matteo, Battaglia, Florinda, Colicchio, Salvatore, Perugi, Giulio
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3056173/
https://www.ncbi.nlm.nih.gov/pubmed/21430794
http://dx.doi.org/10.2147/NDT.S16382

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3056173/
https://www.ncbi.nlm.nih.gov/pubmed/21430794
http://dx.doi.org/10.2147/NDT.S16382

Ejemplares similares